Social Media Ideas for Top Pharma Strategy

<![CDATA[How Pharma is Adjusting Strategies for Changing Dynamics at FDA]]>

<![CDATA[Rethinking Pharma's Go-to-Market Formula]]>

<![CDATA[How Regulatory Stringency, Demand Shocks, and Repurposing Reshape Biopharma Strategy in 2026]]>

<![CDATA[Nuvation Bio’s Global Strategy]]>

Novartis’ strategy in 2026: rebuilding the pipeline after Entresto 

Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking. The post Novartis’ strategy in 2026: r...

Why Execution Excellence Now Defines Biopharma Winners

Strategy matters—but execution separates leaders. Hear how top biopharma teams translate strategy into results.

Inside Takeda’s transformation: The pipeline strategy behind its next growth chapter

With a major restructuring currently underway, we take a look at Takeda's pipeline strategy – including three planned major drug launches. The post Inside Takeda’s transformation:...

<![CDATA[How is Boehringer Ingelheim's Deliberate GLP-1 Strategy Different From Competitors?]]>

<![CDATA[Novavax's Strategy Across Commercial, R&D, and Partnerships]]>

<![CDATA[Supply Chain Modernization is Now Strategy: What Pharma Leaders Must Get Right]]>

Pharma Stocks In Focus: Semaglutide Opportunities And Revlimid Challenges

The pharmaceutical sector continues to offer opportunities. Business Today TV’s Shailendra Bhatnagar discussed with Vaibhav Sanghavi, CEO of ASK Hedge Solutions, that investors sh...

<![CDATA[What Pharma Leaders Must Get Right for Supply Chain Modernization Strategy]]>

9 Effective Pharmaceutical Marketing Strategies (with Examples and 4Ps)

Pharmaceutical marketing comes with its unique challenges and opportunities. And we know that your aim, as a pharmaceutical marketing professional,  is to craft strategies that not...

<![CDATA[Regulatory Changes: Market Access Strategy Can No Longer Wait Until Launch ]]>

How Daiichi Sankyo aims to become a top five oncology player by 2035

Discover Daiichi Sankyo's pipeline strategy, including how it aims to become a top-five global oncology company by 2035. The post How Daiichi Sankyo aims to become a top five oncol...

<![CDATA[What’s Next in Access & Affordability: A Biopharma Perspective]]>

<![CDATA[The Implications of GLP-1s Replacing Oncology as the Key Value Driver]]>

Pharma: Can India take advantage of a China+1 opportunity

Entry Japan with Clarity, Execute with Confidence

For biopharmaceutical companies, Japan is one of the world’s most important markets, but also among the most operationally complex. Many therapies with strong global clinical valid...

Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline...

<![CDATA[What Pharma Investors Should Expect in the Current Regulatory Environment]]>

How integrated strategy is reshaping biopharma growth

RevHealth CEO Ben Beckley shares how integrated teams are helping biopharma organizations align strategy, break down silos and drive stronger commercial impact.

<![CDATA[The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026...

Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy

In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D., Ph.D., detailed how the company leveraged two recent deals to quickly build up its portfolio in Alzh...